

## CDC Immunization Information Systems (IIS) Vaccine Code Set Release Notes

**Vaccine Code Set Update Publication Date: September 15, 2026**

*The individual filenames included in this distribution contain the publication date (20260915)*

**Release Notes:** Release notes provide a technical summary of the updates made to vaccine code sets and crosswalks. This code set release includes only the Fall 2026 COVID-19 Vaccine Codes and Crosswalk summary table. It does not include updates for all regular vaccine-related codes. It also does not include updates to codes for Vaccine Information Statements (VIS).

**General Note Regarding This Release:** This release provides a *preview* of the codes, via the Fall 2026 COVID-19 Vaccine Codes and Crosswalk table, which will be incorporated into the next full Vaccine Code Set release targeted for the week of September 21, 2026. This *preview* is being released to provide situational awareness and enable data partners to commence readying health information systems in anticipation of the next full Vaccine Code Set release.

CDC adds, retires, and takes other actions regarding National Drug Code (NDC) codes, Current Procedural Terminology (CPT) codes, and supporting information into the CDC Vaccine Code Sets upon receiving and processing the necessary information from the manufacturers, FDA, AMA, and NIH, among other data partners. This processing of codes into relational, cross-walked code sets enables vaccines to be actionable, such as for ordering, inventorying, administering, documenting, billing, reporting, and other purposes as applicable.

You may monitor and find the date of the most recent code set publication with a downloadable version of the associated release notes at the CDC Vaccine Code Sets website here: [www.cdc.gov/iis/code-sets/index.html](http://www.cdc.gov/iis/code-sets/index.html)

### 1. New Fall 2026 COVID-19 Vaccine Codes and Crosswalks table

The Fall 2026 COVID-19 Vaccine Codes and Crosswalk table may be found and downloaded at the CDC Vaccine Code Sets website here: [www.cdc.gov/iis/code-sets/fall-season-respiratory-codes.html#heading-gzmlsyi4ss](http://www.cdc.gov/iis/code-sets/fall-season-respiratory-codes.html#heading-gzmlsyi4ss)

All Fall 2026 COVID-19 vaccine products listed below are approved under BLA licensure by the FDA effective August 27, 2026.

## CDC Immunization Information Systems (IIS) Vaccine Code Set Release Notes

### Fall 2026 COVID-19 Vaccine Codes and Crosswalks

| Manufacturer (MVX) | Product Label Tradename                               | CVX Code | CVX Term Description                                                                                         | CVX Short Description                                  | NDC Virus Strain                       | UoS NDC10<br>UoS NDC11        | Packaging                            | UoU NDC10<br>UoU NDC11        | Age Cohort (*)<br><br>Presentation                                                       | CPT Code | CPT Description                                                                                                                                                                                       |
|--------------------|-------------------------------------------------------|----------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|----------------------------------------|-------------------------------|--------------------------------------|-------------------------------|------------------------------------------------------------------------------------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pfizer (PFR)       | COMIRNATY (COVID-19 Vaccine, mRNA, 2026/2027 Formula) | 309      | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | SARS-CoV-2 JN.1-descendent variant XFG | 0069-2631-10<br>00069-2631-10 | CARTON, 10 PRE-FILLED GLASS SYRINGES | 0069-2631-01<br>00069-2631-01 | Ages 12 years and older<br><br>SYRINGE, PRE-FILLED, GLASS, 30 mcg/0.3 mL - DO NOT FREEZE | 91320    | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| Pfizer (PFR)       | COMIRNATY (COVID-19 Vaccine, mRNA, 2026-2027 Formula) | 310      | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | SARS-CoV-2 JN.1-descendent variant XFG | 0069-2609-10<br>00069-2609-10 | CARTON, 10 SINGLE-DOSE VIALS         | 0069-2609-01<br>00069-2609-01 | Ages 5 through 11 years.<br><br>VIAL, SINGLE-DOSE, 10 mcg/0.3 mL DO NOT DILUTE           | 91319    | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine,                                                                                                |

### CDC Immunization Information Systems (IIS) Vaccine Code Set Release Notes

|               |                                                      |     |                                                                                                |                                          |                                        |                               |                                |                               |                                                                    |       |                                                                                                                                                              |
|---------------|------------------------------------------------------|-----|------------------------------------------------------------------------------------------------|------------------------------------------|----------------------------------------|-------------------------------|--------------------------------|-------------------------------|--------------------------------------------------------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
|               |                                                      |     |                                                                                                |                                          |                                        |                               |                                |                               |                                                                    |       | mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use                                                               |
| Moderna (MOD) | SPIKEVAX (COVID-19 Vaccine, mRNA, 2026-2027 Formula) | 312 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | SARS-CoV-2 JN.1-descendent variant XFG | 80777-114-96<br>80777-0114-96 | CARTON, 10 PRE-FILLED SYRINGES | 80777-114-01<br>80777-0114-01 | Ages 12 years and older.<br><br>SYRINGE, PRE-FILLED, 50 mcg/0.5 mL | 91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use |

### CDC Immunization Information Systems (IIS) Vaccine Code Set Release Notes

|               |                                                       |     |                                                                                                 |                                           |                                        |                               |                                |                               |                                                                            |       |                                                                                                                                                               |
|---------------|-------------------------------------------------------|-----|-------------------------------------------------------------------------------------------------|-------------------------------------------|----------------------------------------|-------------------------------|--------------------------------|-------------------------------|----------------------------------------------------------------------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Moderna (MOD) | mNEXSPIKE (COVID-19 Vaccine, mRNA, 2026-2027 Formula) | 334 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2 mL dose  | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL  | SARS-CoV-2 JN.1-descendent variant XFG | 80777-401-60<br>80777-0401-60 | CARTON, 10 PRE-FILLED SYRINGES | 80777-401-17<br>80777-0401-17 | Ages 12 years and older.<br><br>SYRINGE, PRE-FILLED, 10 mcg/0.2 mL         | 91323 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use  |
| Moderna (MOD) | SPIKEVAX (COVID-19 Vaccine, mRNA, 2026-2027 Formula)  | 311 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | SARS-CoV-2 JN.1-descendent variant XFG | 80777-115-80<br>80777-0115-80 | CARTON, 10 PRE-FILLED SYRINGES | 80777-115-09<br>80777-0115-09 | Ages 6 months through 11 years.<br><br>SYRINGE, PRE-FILLED, 25 mcg/0.25 mL | 91321 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use |

## CDC Immunization Information Systems (IIS) Vaccine Code Set Release Notes

|                 |                                                                           |     |                                                                                                                                                                   |                                                                                  |                                                   |                                           |                                          |                                           |                                                                                                      |       |                                                                                                                                                                                                                                                                                                               |
|-----------------|---------------------------------------------------------------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------------------------------|-------------------------------------------|------------------------------------------|-------------------------------------------|------------------------------------------------------------------------------------------------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                 |                                                                           |     |                                                                                                                                                                   |                                                                                  |                                                   |                                           |                                          |                                           |                                                                                                      |       |                                                                                                                                                                                                                                                                                                               |
| Sanofi<br>(PMC) | NUVAXOVID<br>(COVID-19<br>Vaccine,<br>Adjuvanted<br>2026-2027<br>Formula) | 313 | SARS-COV-2<br>(COVID-19)<br>vaccine, subunit,<br>recombinant spike<br>protein-<br>nanoparticle+Matrix<br>-M1 Adjuvant,<br>preservative free, 5<br>mcg/0.5 mL dose | COVID-19,<br>subunit, rS-<br>nanoparticle,<br>adjuvanted,<br>PF, 5<br>mcg/0.5 mL | SARS-CoV-<br>2 JN.1-<br>descendent<br>variant XFG | 49281-<br>026-50<br>49281-<br>0026-<br>50 | CARTON,<br>10 PRE-<br>FILLED<br>SYRINGES | 49281-<br>026-88<br>49281-<br>0026-<br>88 | Ages 12<br>years and<br>older.<br><br>SYRINGE,<br>PRE-FILLED,<br>5 mcg/0.5<br>mL<br>DO NOT<br>FREEZE | 91304 | Severe<br>acute<br>respiratory<br>syndrome<br>coronavirus<br>2 (SARS-<br>CoV-2)<br>(coronavirus<br>disease<br>[COVID-19])<br>vaccine,<br>recombinant<br>spike<br>protein<br>nanoparticle<br>, saponin-<br>based<br>adjuvant,<br>preservative<br>free, 5<br>mcg/0.5 mL<br>dosage, for<br>intramuscul<br>ar use |

(\*) FDA approved age cohort for each vaccine formulation is shown, subject to eligibility guidance from FDA and CDC.

## CDC Immunization Information Systems (IIS) Vaccine Code Set Release Notes

### Access to CDC Vaccine Code Sets

CDC provides additional methods to access the vaccine codes in addition to the files and content found on CDC's Vaccine Code Sets website here: [www.cdc.gov/iis/code-sets/index.html](http://www.cdc.gov/iis/code-sets/index.html).

You are encouraged to explore the following additional methods available here: [www.cdc.gov/iis/code-sets/viewpoint-rest.html](http://www.cdc.gov/iis/code-sets/viewpoint-rest.html):

- The **Viewpoint Vaccine Code Set Browser** provides dynamic browse and search capabilities against the entire Vaccine Code Set.
- The **Runtime REST Web Service** provides improved access to Vaccine Code Sets data by providing a way for development teams and other technical users to query and receive vaccine code data via API.
- The **Content Cloud Portal** provides delivery and download of desired reports. Access and file subscriptions are managed by registration.

For questions or need further assistance with any of the additional methods mentioned above please email [iisinfo@cdc.gov](mailto:iisinfo@cdc.gov).